Surmodics Stock Price, News & Analysis (NASDAQ:SRDX) $33.64 +0.25 (+0.75%) (As of 12/4/2023 ET) Add Compare Share Share Today's Range$32.93▼$34.0150-Day Range$28.47▼$35.0952-Week Range$16.00▼$39.41Volume42,184 shsAverage Volume107,834 shsMarket Capitalization$476.21 millionP/E RatioN/ADividend YieldN/APrice Target$57.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Surmodics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside70.9% Upside$57.50 Price TargetShort InterestHealthy1.73% of Float Sold ShortDividend StrengthN/ASustainability-2.52Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.00) to ($0.29) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.22 out of 5 starsMedical Sector332nd out of 952 stocksSurgical & Medical Instruments Industry39th out of 89 stocks 3.5 Analyst's Opinion Consensus RatingSurmodics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $57.50, Surmodics has a forecasted upside of 70.9% from its current price of $33.64.Amount of Analyst CoverageSurmodics has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.73% of the float of Surmodics has been sold short.Short Interest Ratio / Days to CoverSurmodics has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Surmodics has recently increased by 71.00%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSurmodics does not currently pay a dividend.Dividend GrowthSurmodics does not have a long track record of dividend growth. Previous Next 3.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSurmodics has received a 38.03% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Synthetic antigens", " Coatings for drug delivery devices", and "Medical equipment engineering" products. See details.Environmental SustainabilityThe Environmental Impact score for Surmodics is -2.52. Previous Next 2.5 News and Social Media Coverage News SentimentSurmodics has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Surmodics this week, compared to 1 article on an average week.Search Interest1 people have searched for SRDX on MarketBeat in the last 30 days. MarketBeat Follows3 people have added Surmodics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Surmodics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.50% of the stock of Surmodics is held by insiders.Percentage Held by Institutions87.09% of the stock of Surmodics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Surmodics are expected to grow in the coming year, from ($1.00) to ($0.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Surmodics is -280.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Surmodics is -280.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSurmodics has a P/B Ratio of 3.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Surmodics Stock (NASDAQ:SRDX)Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.Read More SRDX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SRDX Stock News HeadlinesNovember 16, 2023 | finance.yahoo.comSurmodics Announces 24-Month Data from the SWING Trial Presented at VEITHsymposiumNovember 16, 2023 | finance.yahoo.comSurmodics Announces TRANSCEND Trial 36-Month Data Presented at 50th Annual VEITH SymposiumDecember 5, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 15, 2023 | finance.yahoo.comSurmodics, Inc.'s (NASDAQ:SRDX) Intrinsic Value Is Potentially 91% Above Its Share PriceNovember 14, 2023 | finance.yahoo.comSurmodics to Participate in the Piper Sandler Healthcare Conference on November 28November 11, 2023 | finance.yahoo.comSurmodics, Inc. (NASDAQ:SRDX) Q4 2023 Earnings Call TranscriptNovember 10, 2023 | markets.businessinsider.comSurModics Outperforms Projections: Encouraging Financial Results and Promising Product Portfolio Prompt Buy Rating and Raised Price TargetNovember 9, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Altimmune (ALT) and SurModics (SRDX)December 5, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 8, 2023 | finance.yahoo.comSurModics (SRDX) Reports Q4 Earnings: What Key Metrics Have to SayNovember 8, 2023 | finance.yahoo.comSurmodics Inc (SRDX) Reports Fiscal Year 2023 Earnings Growth and Introduces FY 2024 GuidanceNovember 8, 2023 | finance.yahoo.comSurmodics Reports Fourth Quarter and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Financial GuidanceNovember 7, 2023 | finance.yahoo.comSurmodics Announces TRANSCEND Trial 36-Month Data to be Presented at 50th Annual VEITH SymposiumNovember 7, 2023 | finance.yahoo.comSurmodics Announces SWING Trial 24-Month Data to be Presented at VEITH Symposium on November 15October 31, 2023 | finance.yahoo.comSurmodics Announces Launch of Preside™ Medical Device Coating Technology, Providing Industry-Leading Lubricity and Durability to a Broader Range of Complex Device ApplicationsOctober 10, 2023 | finance.yahoo.comSurmodics to Report Fourth Quarter and Fiscal 2023 Financial Results on November 8October 6, 2023 | finance.yahoo.comThe past five years for Surmodics (NASDAQ:SRDX) investors has not been profitableSeptember 12, 2023 | finance.yahoo.comSurmodics (SRDX) Hits 52-Week High: What's Driving the Stock?September 6, 2023 | finance.yahoo.comWhy You Should Add Surmodics (SRDX) Stock to Your PortfolioAugust 9, 2023 | finance.yahoo.comSurmodics to Participate in Upcoming Investor Conferences in AugustAugust 3, 2023 | finance.yahoo.comSurmodics (SRDX) Q3 Earnings Top Estimates, FY23 View UpAugust 3, 2023 | msn.comNeedham Reiterates Surmodics (SRDX) Buy RecommendationAugust 2, 2023 | finance.yahoo.comSurmodics Reports Third Quarter of Fiscal Year 2023 Financial Results; Updates Fiscal Year 2023 Financial GuidanceAugust 2, 2023 | finance.yahoo.comSurModics (SRDX) Surpasses Q3 Earnings and Revenue EstimatesAugust 2, 2023 | finance.yahoo.comSurModics (SRDX) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesJuly 12, 2023 | finance.yahoo.comSurmodics to Report Third Quarter of Fiscal 2023 Financial Results on August 2June 28, 2023 | finance.yahoo.comThree Reasons to Add Surmodics (SRDX) Stock to Your PortfolioSee More Headlines Receive SRDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Surmodics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2023Today12/05/2023Next Earnings (Estimated)2/05/2024Fiscal Year End9/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNASDAQ:SRDX CUSIP86887310 CIK924717 Webwww.surmodics.com Phone(952) 500-7000Fax952-500-7001Employees376Year Founded1979Price Target and Rating Average Stock Price Target$57.50 High Stock Price Target$71.00 Low Stock Price Target$44.00 Potential Upside/Downside+70.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,540,000.00 Net Margins-1.16% Pretax Margin1.88% Return on Equity1.99% Return on Assets1.24% Debt Debt-to-Equity Ratio0.25 Current Ratio3.62 Quick Ratio3.00 Sales & Book Value Annual Sales$132.58 million Price / Sales3.59 Cash Flow$0.79 per share Price / Cash Flow42.58 Book Value$8.48 per share Price / Book3.97Miscellaneous Outstanding Shares14,156,000Free Float13,094,000Market Cap$476.21 million OptionableOptionable Beta1.15 Social Links Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Gary R. Maharaj (Age 60)CEO, President & Director Comp: $1.1MMr. Timothy J. Arens (Age 56)Senior VP of Finance & Information Technology and CFO Comp: $545.83kMr. Gordon S. Weber (Age 60)Senior VP of Legal, General Counsel & Secretary Comp: $519.6kMr. Charles W. Olson (Age 59)Senior VP & President of Medical Device Coatings Comp: $523.12kMs. Teryl L. W. Sides (Age 53)Senior VP & President of Vascular Interventions Comp: $613.02kMr. John D. Manders (Age 42)Corporate Controller, VP of Finance & Principal Accounting Officer Mr. Joseph J. Stich (Age 58)Senior VP of Human Resources & President of In Vitro Diagnostics Comp: $570.92kMore ExecutivesKey CompetitorsOrthofix MedicalNASDAQ:OFIXAngioDynamicsNASDAQ:ANGOAccurayNASDAQ:ARAYAlphatecNASDAQ:ATECAtriCureNASDAQ:ATRCView All CompetitorsInstitutional OwnershipDeutsche Bank AGBought 1,108 shares on 11/24/2023Ownership: 0.050%Jacobs Levy Equity Management Inc.Sold 20,137 shares on 11/17/2023Ownership: 0.989%Tudor Investment Corp Et AlBought 33,996 shares on 11/16/2023Ownership: 0.241%Royal Bank of CanadaBought 1,997 shares on 11/15/2023Ownership: 0.408%Ameriprise Financial Inc.Bought 2,078 shares on 11/15/2023Ownership: 0.360%View All Institutional Transactions SRDX Stock Analysis - Frequently Asked Questions Should I buy or sell Surmodics stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Surmodics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SRDX shares. View SRDX analyst ratings or view top-rated stocks. What is Surmodics' stock price target for 2024? 2 brokers have issued 1 year price targets for Surmodics' stock. Their SRDX share price targets range from $44.00 to $71.00. On average, they expect the company's share price to reach $57.50 in the next year. This suggests a possible upside of 70.9% from the stock's current price. View analysts price targets for SRDX or view top-rated stocks among Wall Street analysts. How have SRDX shares performed in 2023? Surmodics' stock was trading at $34.12 on January 1st, 2023. Since then, SRDX stock has decreased by 1.4% and is now trading at $33.64. View the best growth stocks for 2023 here. Are investors shorting Surmodics? Surmodics saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 235,300 shares, an increase of 71.0% from the October 31st total of 137,600 shares. Based on an average trading volume of 63,100 shares, the days-to-cover ratio is currently 3.7 days. Approximately 1.7% of the shares of the stock are short sold. View Surmodics' Short Interest. When is Surmodics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, February 5th 2024. View our SRDX earnings forecast. How were Surmodics' earnings last quarter? Surmodics, Inc. (NASDAQ:SRDX) released its earnings results on Wednesday, November, 8th. The company reported $0.53 EPS for the quarter, topping analysts' consensus estimates of $0.16 by $0.37. The company had revenue of $27.97 million for the quarter, compared to analyst estimates of $26 million. Surmodics had a negative net margin of 1.16% and a positive trailing twelve-month return on equity of 1.99%. What ETF holds Surmodics' stock ? Invesco Nasdaq Future Gen 200 ETF holds 1,909 shares of SRDX stock, representing 0.85% of its portfolio. What guidance has Surmodics issued on next quarter's earnings? Surmodics issued an update on its FY 2024 earnings guidance on Wednesday, November, 8th. The company provided earnings per share guidance of -$1.32--$0.97 for the period, compared to the consensus estimate of -$0.20. The company issued revenue guidance of $112.00 million-$117.00 million, compared to the consensus revenue estimate of $130.88 million. What is Gary Maharaj's approval rating as Surmodics' CEO? 8 employees have rated Surmodics Chief Executive Officer Gary Maharaj on Glassdoor.com. Gary Maharaj has an approval rating of 65% among the company's employees. What other stocks do shareholders of Surmodics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Surmodics investors own include Gilead Sciences (GILD), Netflix (NFLX), Exelixis (EXEL), Intel (INTC), NVIDIA (NVDA), Tandem Diabetes Care (TNDM), uniQure (QURE), Sangamo Therapeutics (SGMO), Abbott Laboratories (ABT) and Dynavax Technologies (DVAX). Who are Surmodics' major shareholders? Surmodics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Acadian Asset Management LLC (2.51%), Kennedy Capital Management LLC (1.63%), Jacobs Levy Equity Management Inc. (0.99%), Northern Trust Corp (0.97%), Salem Investment Counselors Inc. (0.91%) and Charles Schwab Investment Management Inc. (0.78%). Insiders that own company stock include Charles W Olson, Charles W Olson, David Dantzker, Gary R Maharaj, John D Manders, Jose H Bedoya, Jose H Bedoya, Joseph J Stich, Joseph J Stich and Ronald B Sr Kalich Sr. View institutional ownership trends. How do I buy shares of Surmodics? Shares of SRDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:SRDX) was last updated on 12/5/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Surmodics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.